BusinessWeek calls Genocea Biosciences 1 of world's most intriguing startups

Genocea Biosciences, a vaccine discovery and development company, announced Nov. 16 that it was named one of BusinessWeek’s “World’s Most Intriguing Startups” for 2009.

Genocea, whose vaccine development is based on mimicking the human body’s natural immune processes, was only one of two biotechnology companies recognized by BusinessWeek in its inaugural list of 25 global companies.

 “Genocea’s proprietary platform has the ability to rapidly accelerate vaccine discovery and development from years to months, thereby speeding global access to vaccines to treat and eradicate some of the world’s most deadly and infectious diseases,” said Staph Leavenworth Bakali, CEO and president of Genocea Biosciences.

Its approach to vaccine development includes identifying novel targets for vaccines based on what humans respond to naturally during infection. The company employs a rapid and proprietary process to screen and identify thousands of potentially human protective antigens to identify the critical components for vaccine effectiveness.

The company is developing vaccines for some of the world’s most complex pathogens, and its current portfolio includes therapeutic and prophylactic vaccine candidates for Chlamydia trachomatis, Streptococcus pneumoniae and other undisclosed targets.